Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib

Background: Alterations in MET exon 14 (METex14) and its flanking intronic regions have been identified in a variety of cancers. Patients with METex14 alterations often benefit from MET inhibitors such as crizotinib. Given the unique mutation profiles of Chinese lung cancer patients, it is necessary...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Tianli, Gu, Zhongping, Song, Danni, Liu, Sisi, Tong, Xiaoling, Wu, Xue, Lin, Zhifeng, Hong, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778531/
https://www.ncbi.nlm.nih.gov/pubmed/33403024
http://dx.doi.org/10.7150/jca.49391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778531/
https://www.ncbi.nlm.nih.gov/pubmed/33403024
http://dx.doi.org/10.7150/jca.49391

Ejemplares similares